We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
IVERIC bio Inc | NASDAQ:ISEE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 39.95 | 43.94 | 37.96 | 0 | 01:00:00 |
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company will participate in the following upcoming virtual investor conferences in September:
The Company will also participate in the following retina showcase:
About IVERIC bio
IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com.
Forward-looking Statements
Any statements in this press release about IVERIC bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent IVERIC bio’s views only as of the date of this press release. IVERIC bio anticipates that subsequent events and developments will cause its views to change. While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.
ISEE-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005119/en/
Investor Contact: IVERIC bio Kathy Galante, 212-845-8231 Vice President, Investor Relations and Corporate Communications kathy.galante@ivericbio.com
or
Media Contact: SmithSolve Alex Van Rees, 973-442-1555 ext. 111 alex.vanrees@smithsolve.com
1 Year IVERIC bio Chart |
1 Month IVERIC bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions